Evidence map›Paper›PMID 38594599›Full record

ArticleJournal of nephrology2024

Improving outcomes in atherosclerotic renovascular disease: importance of clinical presentation and multi-disciplinary review.

Áine M de Bhailis, Edward Lake, Constantina Chrysochou, Darren Green, Rajkumar Chinnadurai, Philip A Kalra

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Journal of nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Testosterone deficiency and chronic kidney disease.Journal of clinical & translational endocrinology · 2024
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Áine M de BhailisDepartment of Renal Medicine, Salford Royal NHS Foundation Trust, Salford, M6 8HD, UK. aine.debhailis@nca.nhs.uk.ORCID 0000-0002-6223-5601
Edward LakeDepartment of Vascular Interventional Radiology, Manchester University NHS Foundation Trust, Manchester, UK.
Constantina ChrysochouDepartment of Renal Medicine, Salford Royal NHS Foundation Trust, Salford, M6 8HD, UK.
Darren GreenDepartment of Renal Medicine, Salford Royal NHS Foundation Trust, Salford, M6 8HD, UK.
Rajkumar ChinnaduraiDepartment of Renal Medicine, Salford Royal NHS Foundation Trust, Salford, M6 8HD, UK.
Philip A KalraDepartment of Renal Medicine, Salford Royal NHS Foundation Trust, Salford, M6 8HD, UK.
Salford Royal NHS Foundation Trust · GBManchester Academic Health Science Centre · GBManchester University NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesAtherosclerotic renal artery stenosis may cause hypertension, chronic kidney disease and heart failure, but large randomized control trials to date have shown no major additional benefit of renal revascularization over optimal medical management. However, these trials did not consider outcomes specifically in relation to clinical presentations. Given that atherosclerotic renal artery stenosis is a heterogenous condition, measures of success likely differ according to the clinical presentation. Our retrospective study objectives were to determine the effects of revascularization when applied to specific clinical presentations and after careful multi-disciplinary team review.

methodsAll patients presenting to our centre and its referring hospitals with radiological findings of at least one renal artery stenosis > 50% between January 2015 and January 2020 were reviewed at the renovascular multi-disciplinary team meeting with revascularization considered in accordance with international guidelines, notably for patients with anatomically significant renal artery stenosis, adequately sized kidney and presentations with any of; deteriorating kidney function, heart failure syndrome, or uncontrollable hypertension. Optimal medical management was recommended for all patients which included lipid lowering agents, anti-platelets and anti-hypertensives targeting blood pressure ≤ 130/80 mmHg. The effect of revascularization was assessed according to the clinical presentation; blood pressure and number of agents in those with renovascular hypertension, delta glomerular filtration rate in those with ischaemic nephropathy and heart failure re-admissions in those with heart failure syndromes.

resultsDuring this 5-year period, 127 patients with stenosis ≥ 50% were considered by the multidisciplinary team, with 57 undergoing revascularization (17 primarily for severe hypertension, 25 deteriorating kidney function, 6 heart failure syndrome and 9 for very severe anatomical stenosis). Seventy-nine percent of all revascularized patients had a positive outcome specific to their clinical presentation, with 82% of those with severe hypertension improving blood pressure control, 72% with progressive ischaemic nephropathy having attenuated GFR decline, and no further heart failure admissions in those with heart failure. Seventy-eight percent of patients revascularized for high grade stenosis alone had better blood pressure control with 55% also manifesting renal functional benefits.

conclusionsMulti-disciplinary team discussion successfully identified a group of patients more likely to benefit from revascularization based on 3 key factors: clinical presentation, severity of the renal artery lesion and the state of the kidney beyond the stenotic lesion. In this way, a large proportion of patients can clinically improve after revascularization if their outcomes are considered according to the nature of their clinical presentation.

Indexed as

Hypertension, RenovascularRenal Artery ObstructionAgedAntihypertensive AgentsAtherosclerosisFemaleGlomerular Filtration RateHumansMaleMiddle AgedPatient Care TeamRetrospective StudiesTreatment OutcomeAntihypertensive AgentsHypertensionRenal artery stenosisRenovascular diseaseRevascularization

Identifiers

PMID38594599
PMCPMC11239762
OpenAlexW4394600575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.